Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15608178 | 1.00 | POLB (0.46) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL3178302 | 0.83 | POLB (0.44) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL28393769 | 0.83 | POLB (0.44) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL15207774 | 0.83 | POLB (0.44) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL3178313 | 0.83 | POLB (0.44) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL3182268 | 0.83 | POLB (0.44) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL16612137 | 0.83 | POLB (0.44) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL7298229 | 0.80 | POLB (0.42) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL29026531 | 0.80 | POLB (0.42) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL20399403 | 0.80 | POLB (0.42) | POLBL3MBTL1CHRNB2CHRNA5CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10064839-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9561209-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-2705030-B1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9290472-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012154676-A9 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-2705030-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | POLB 2073/4885L3MBTL1 4097/4885CHRNB2 3068/4885 |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | POLB 3256/4885L3MBTL1 2681/4885CHRNB2 2675/4885 |
| US-10064839-B2 | Methods of treating liver diseases | ENPEP, GOT2, METAP2 | POLB 3256/4885L3MBTL1 2681/4885CHRNB2 2675/4885 |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | POLB 3256/4885L3MBTL1 2681/4885CHRNB2 2675/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | POLB 2073/4885L3MBTL1 4097/4885CHRNB2 3068/4885 |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | DNPEP, CES2, AADAC | POLB 2073/4885L3MBTL1 4097/4885CHRNB2 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.